NEUROMEDICAL SYSTEMS' LAUNCHING PAPNET ANALYZER DEC. 1 AT PRICE TO LABS OF $18 PER TEST; PLANNED IPO TO NET $75.1 MIL., FUND MARKETING AND EXPANSION EFFORT
This article was originally published in The Gray Sheet
Executive Summary
Neuromedical Systems, Inc. is rolling out its Papnet adjunctive Pap smear analyzer Dec. 1 following FDA approval of the product's premarket approval application Nov. 8. Neuromedical Systems, Inc. is offering the system, designed to increase detection of positive samples, to labs at a cost of $18 per slide. NSI estimates the cost to patients at $35.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.